All patients with Paget's disease should receive 1500 mg of calcium in divided doses and 800 IU of vitamin D daily, particularly in the two weeks following Reclast administration. It is recommended that patients with postmenopausal osteoporosis take calcium and vitamin D supplements, if dietary intake is not sufficient.
For more information about Reclast, visit http://www.reclast.com or call 866-RECLAST (866-732-5278).
The foregoing press release contains forward-looking statements that
can be identified by the use of forward-looking terminology such as
"potential", "anticipated", "generally follows", "expected", "hope",
"will", or similar expressions, or by express or implied discussions
regarding potential future regulatory approvals of Reclast/Aclasta, or
potential future sales of Reclast/Aclasta. Such forward-looking statements
reflect the current views of Novartis regarding future events, and involve
known and unknown risks, uncertainties and other factors that may cause
actual results to be materially different from any future results,
performance or achievements expressed or implied by such statements. There
can be no guarantee that Reclast/Aclasta will be approved for sale, or for
any additional indications or labeling in any market, or that
Reclast/Aclasta will reach any particular level of sales. In particular,
management's expectations regarding Reclast/Aclasta could be affected by,
among other things, unexpected reg
|SOURCE Novartis Pharmaceuticals Corporation|
Copyright©2007 PR Newswire.